Continuous Glucose Monitoring in Patients with Type 1 Diabetes and Impaired Awareness of Hypoglycemia: Also Effective in Patients with Psychological Distress?

2017 ◽  
Vol 19 (10) ◽  
pp. 595-599 ◽  
Author(s):  
Cornelis A.J. van Beers ◽  
Maartje de Wit ◽  
Susanne J. Kleijer ◽  
Petronella H. Geelhoed-Duijvestijn ◽  
J. Hans DeVries ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Psychological Distress ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Impaired Awareness

scholarly journals An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England

2017 ◽  
Vol 13 (02) ◽  
pp. 81 ◽  
Author(s):  
Shraddha Chaugule ◽  
Nick Oliver ◽  
Brigitte Klinkenbijl ◽  
Claudia Graham ◽  
◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Budget Impact ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Published Data ◽  
North West ◽  
Impaired Awareness Of Hypoglycaemia ◽  
Impaired Awareness

Objective: To assess the economic impact of providing real time continuous glucose monitoring (CGM) for people with type 1 diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) within North West (NW) London clinical commissioning groups (CCGs). Methods: The eligible population for CGM and inputs for the economic budget impact model developed were derived from published data. The model includes cost of CGM; cost savings associated with lower hypoglycaemia related hospital admissions, accidents and emergency visits; self-monitoring of blood glucose (SMBG) strip usage; and glycated haemoglobin (HbA1c) reduction-related avoided complications and insulin pump use. Results: The cost of CGM for T1D-IAH (n=3,036) in the first year is £10,770,671 and in the fourth year is £11,329,095. The combined cost off-sets related to reduced hypoglycaemia admissions, SMBG strip usage and complications are £8,116,912 and £8,741,026 in years one and four, respectively. The net budget impact within the NW London CCGs is £2,653,760; £2,588,068 in years one and four respectively. Conclusions: Introduction of CGM for T1D-IAH patients will have a minimal budget impact on NW London CCGs, driven by cost of CGM and offsets from lower hypoglycaemia-related costs, reduced SMBG strip usage, avoided HbA1c-related complications and lower insulin pump use.

Sign in / Sign up

Export Citation Format

Share Document